Online citations, reference lists, and bibliographies.
← Back to Search

Summary Of Presentation From The Targeted Therapy In Lung Cancer Meeting.

R. Govindan
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
New pathways are being identified now on a regular basis, and novel agents are being tested in a wide variety of clinical trials for patients with advanced non-small cell lung cancer. Excitement over progress in one area is tempered naturally by disappointing results in other areas. Each year, leading lung cancer experts meet in Santa Monica to discuss the progress in the field of molecularly targeted therapy in non-small cell lung cancer. Annual conferences similar to the one held in Santa Monica serve mainly as a catalyst to promote new ideas and foster active collaboration. We have invited participants to provide very brief succinct summaries of the presentations for this supplement. The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles.
This paper references
10.1200/JCO.2008.17.2064
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
A. Tolcher (2008)
10.1016/j.ccr.2009.10.015
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Michael Hedvat (2009)
10.1073/pnas.0907781106
Alterations of the Notch pathway in lung cancer
Britta Westhoff (2009)
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
D. Siemann (2008)
10.1056/NEJMoa1002011
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
Molecular analysis identifies a subset of non-small cell lung cancer patients with differential sensitivity to histone deacetylase inhibitor/epidermal growth factor receptor tyrosine kinase treatment
R M Jotte (2010)
10.1200/JCO.2007.25.18_SUPPL.7589
A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)
V. Papadimitrakopoulou (2007)
10.1158/1078-0432.CCR-10-2745
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
P. LoRusso (2011)
10.1016/J.YONC.2011.10.023
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
K. Gelmon (2011)
10.1200/JCO.2010.28.18_SUPPL.LBA7501
A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.
J. von Pawel (2010)
Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
C. Bondzi (2000)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
10.1378/CHEST.125.5_SUPPL.101S
Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo.
K. West (2004)
10.1038/35106079
Histone deacetylases and cancer: causes and therapies
P. Marks (2001)
10.2174/156802609789895737
Purine-scaffold Hsp90 inhibitors.
Tony Taldone (2009)
10.1158/1078-0432.CCR-07-1610
The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage
D. Chen (2007)
10.1200/JCO.2009.24.7353
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
D. Spigel (2010)
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
L. Krug (2000)
10.1097/JTO.0b013e3181653cf4
Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer
T. Stinchcombe (2008)
10.1200/JCO.2010.30.8338
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
L. Sequist (2010)
10.1200/JCO.2010.28.18_SUPPL.LBA7511
Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
M. Socinski (2010)
10.1200/JCO.2010.28.15_SUPPL.7052
Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).
M. O'Brien (2010)
EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells
A M Gobin (2008)
10.1200/JCO.2010.28.15_SUPPL.3089
Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.
A. Jimeno (2010)
10.1200/JCO.2010.28.15_SUPPL.3104
Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.
J. Desai (2010)
10.1158/1078-0432.CCR-07-0793
Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids
J. He (2007)
10.1016/S1359-6349(10)72119-4
412 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors
Q. Chu (2010)
Randomized double-blind placebocontrolled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer
S M Lee (2009)
Smac mimetics and TNFalpha: a dangerous liaison?
Hao Wu (2007)
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage nonsmall-cell lung cancer
L Paz-Ares (2006)
10.1200/JCO.2010.28.18_SUPPL.LBA513
ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.
M. Ellis (2010)
10.1097/JTO.0b013e3181eba657
Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial
N. Ready (2010)
10.1007/s10555-009-9185-8
Kinesin motor proteins as targets for cancer therapy
D. Huszar (2009)
10.1158/1078-0432.CCR-10-0992
Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome
L. Stabile (2010)
10.1126/scitranslmed.3002003
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
L. Sequist (2011)
10.1200/JCO.2009.21.9618
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
T. Lynch (2010)
10.1158/1078-0432.CCR-08-0378
Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
A. Ricart (2008)
10.1074/jbc.M109.040139
X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists
E. Varfolomeev (2009)
10.1200/JCO.2010.31.6208
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
L. Gandhi (2011)
10.1158/1078-0432.CCR-07-1310
A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
K. Chi (2008)
10.1200/JCO.2007.14.4824
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
K. Kelly (2008)
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.
M. Kinch (2003)
10.1016/j.molcel.2010.06.017
The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.
Raga Krishnakumar (2010)
10.1200/JCO.2009.23.6745
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
A. Tolcher (2009)
10.1200/JCO.2007.14.5466
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
M. Reck (2009)
10.1517/14712598.2010.484801
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
A. Chiappori (2010)
10.1002/gcc.20604
Expression and mutational analysis of MET in human solid cancers
P. Ma (2008)
10.1158/1078-0432.CCR-10-0017
EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
J. Lee (2010)
10.1038/clpt.2010.34
Hunting the Hedgehog Pathway
G. Weiss (2010)
10.1200/JCO.2009.23.7545
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
L. Horn (2009)
10.1158/0008-5472.CAN-08-4327
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
U. McDermott (2009)
Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer
C S Karapetis (2010)
10.1126/science.1183057
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
K. Sugahara (2010)
10.1074/jbc.M109.075085
EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation*
L. Faoro (2010)
10.1158/1535-7163.MCT-04-0345
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
M. Jordan (2005)
10.1200/JCO.2006.09.7097
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
J. Vansteenkiste (2007)
Estrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomized controlled trial
R T Chlebowski (2009)
10.1158/1078-0432.CCR-06-1606
A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
E. Rowinsky (2007)
10.1093/JNCI/91.2.151
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.
H. Yu (1999)
Activity of IPI504 , a novel heatshock protein 90 inhibitor , in patients with molecularly defined non - small - cell lung cancer
LV Sequist (2010)
10.1158/1535-7163.MCT-08-0986
Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies
C. Dumontet (2009)
10.1200/JCO.2010.28.15_SUPPL.7503
Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.
P. Jänne (2010)
10.1097/JTO.0b013e3181ec1531
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
K. Price (2010)
10.1016/S0140-6736(09)60569-9
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
R. Pirker (2009)
10.1093/JNCI/92.18.1460
Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise.
S. Baylin (2000)
10.1200/JCO.2005.02.4133
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.
J. Tsurutani (2006)
10.1158/1535-7163.MCT-08-0473
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
E. Kawata (2008)
10.1016/J.IJROBP.2006.03.019
Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation.
Yubin Zhang (2006)
10.1158/1078-0432.CCR-10-0631
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
R. Herbst (2010)
10.1158/0008-5472.CAN-03-3241
Tobacco Carcinogen-Induced Cellular Transformation Increases Activation of the Phosphatidylinositol 3′-Kinase/Akt Pathway in Vitro and in Vivo
K. West (2004)
10.1126/science.1141478
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
J. Engelman (2007)
10.1089/109065701753145547
Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
N. Lindor (2001)
10.1016/S1470-2045(08)70209-2
Targeted manipulation of apoptosis in cancer treatment.
J. Call (2008)
10.1200/JCO.2008.26.15_SUPPL.8053
Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2
N. Rizvi (2008)
10.1158/1535-7163.MCT-10-0698
Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
L. Liu (2011)
10.1158/0008-5472.CAN-06-3612
Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.
V. Potiron (2007)
10.1200/JCO.2009.24.9094
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
S. Ramalingam (2010)
Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer.
K. Hibi (1991)
10.1016/j.drudis.2010.01.003
IAP antagonists: promising candidates for cancer therapy.
R. Mannhold (2010)
10.1038/nrm1261
Met, metastasis, motility and more
C. Birchmeier (2003)
10.1016/J.IJROBP.2007.07.2350
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
K. Shibuya (2007)
10.1200/JCO.2009.27.9414
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
L. Sequist (2010)
10.1097/JTO.0b013e31818396a4
Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer
N. Choong (2008)
10.1200/JCO.2005.02.840
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
R. Herbst (2005)
10.1097/JTO.0b013e31817c6b4f
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
R. Ramlau (2008)
10.1200/JCO.2005.03.170
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.
D. Bissett (2005)
10.1016/J.LUNGCAN.2005.10.003
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
J. Tang (2006)
10.1038/sj.onc.1202547
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Laura Schmidt (1999)
10.1001/jama.2010.261
Stereotactic body radiation therapy for inoperable early stage lung cancer.
R. Timmerman (2010)
10.1002/ijc.24759
Vorinostat increases carboplatin and paclitaxel activity in non‐small cell lung cancer cells
T. Owonikoko (2010)
10.1016/0959-8049(95)00438-6
Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines.
C. Papadimitriou (1995)
10.1158/1078-0432.CCR-10-1932
Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
D. Talbot (2010)
Safety and pharmacokinetics of first-line AMG 479 (Mab to IGF1R) or AMG 102 (Mab to HGF/SF) with platinum-based chemotherapy in extensive-stage small cell lung cancer (SCLC)
P Lorigan (2010)
10.1200/JCO.2010.28.15_SUPPL.3005
First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.
H. Burris (2010)
10.1200/JCO.2005.02.857
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
David A. Eberhard (2005)
10.1097/01.JTO.0000283221.63767.BA
C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma
H. Kindler (2007)
10.1200/JCO.2007.14.4741
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
S. Laurie (2008)
10.1124/mol.108.049544
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
L. Marek (2009)
10.1158/1535-7163.MCT-05-0244
Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel
P. Sève (2005)
10.1200/JCO.2009.22.9427
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
G. Goss (2010)
10.1073/pnas.0710370104
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
J. Bean (2007)
10.1158/0008-5472.CAN-10-1489
GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
A. Bai (2010)
10.1056/NEJMoa0905360
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
D. V. Von Hoff (2009)
10.1016/S1470-2045(09)70364-X
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
T. Mitsudomi (2010)
10.1089/cbr.2010.0865
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
A. Tarhini (2010)
10.1093/ANNONC/MDI365
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
G. Dy (2005)
10.1097/JTO.0b013e3181c5e366
Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials
P. Paik (2010)
10.1126/scitranslmed.3001451
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
J. Weiss (2010)
10.1158/1078-0432.CCR-10-2277
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
M. Arcila (2011)
10.1056/NEJMOA061884
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
A. Sandler (2006)
10.4049/jimmunol.181.11.7721
Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists1
A. Wesa (2008)
10.1200/JCO.2004.08.001
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
G. Giaccone (2004)
10.1097/JTO.0b013e31814617b7
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network
D. Spigel (2007)
10.1038/nrc2887
Targeting the dynamic HSP90 complex in cancer
J. Trepel (2010)
10.1200/JCO.2008.19.9331
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
D. Karp (2009)
10.1016/S1470-2045(11)70184-X
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
C. Zhou (2011)
10.1097/00000441-191108000-00079
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
P. Rous (1911)
10.1586/17476348.2.1.37
BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer
E. Powell (2008)
10.1200/JCO.2010.28.15_SUPPL.3016
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
V. Macaulay (2011)
10.1016/0169-5002(92)90235-c
Preferential expression of c-kit protooncogene transcripts in small cell lung cancer.
Y. Sekido (1991)
10.1158/1535-7163.MCT-07-0052
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
A. Tsao (2007)
Neratinib , an irreversible panErbB receptor tyrosine kinase inhibitor : results of a phase II trial in patients with advanced non - small - cell lung cancer
LV Sequist (2010)
10.1593/TLO.09109
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.
N. Desai (2009)
10.1200/jco.2009.27.15_suppl.3503
A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST).
A. Tolcher (2009)
10.1056/NEJMoa0909530
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
M. Maemondo (2010)
10.1038/sj.bjc.6604808
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
M. McKeage (2008)
10.1158/0008-5472.CAN-06-2627
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
A. Das (2006)
10.1093/JNCI/88.18.1308
Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.
C. Milross (1996)
10.1038/sj.bjc.6604676
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
Q. Chang (2008)
10.1093/CARCIN/BGH226
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.
B. Balsara (2004)
10.1200/JCO.2005.01.3771
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
S. Williamson (2005)
10.1038/260170A0
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
D. Stéhelin (1976)
10.1158/1078-0432.CCR-07-0162
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
S. Ramalingam (2007)
10.1158/1078-0432.CCR-06-1058
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer
T. Seiwert (2007)
10.1200/JCO.2005.05.1474
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
U. Gatzemeier (2007)
10.1158/1535-7163.MCT-10-0397
Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics
Kristi E Allen (2010)
10.1158/1078-0432.CCR-10-2662
Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Y. Janjigian (2011)
10.1016/j.cell.2011.02.013
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
10.1200/JCO.2010.28.15_SUPPL.7600
A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC.
G. Blumenthal (2010)
10.1200/JCO.2004.07.215
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
R. Herbst (2004)
10.1097/JTO.0b013e3181bbc540
Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
D. Spigel (2009)
10.1097/JTO.0b013e3182156250
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer
R. Digumarti (2011)
10.1038/nrd2530
Drug development of MET inhibitors: targeting oncogene addiction and expedience
P. Comoglio (2008)
10.1074/jbc.M804103200
Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors*
R. Noberini (2008)
A phase 1 study of IPI-926, an inhibitor of the Hedgehog pathway, in patients with advanced or metastatic solid tumors
C Rudin (2010)
10.1038/NG0597-68
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
L. Schmidt (1997)
10.1517/14728222.2010.515980
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Rachel M. A. Linger (2010)
10.1200/JCO.2007.12.2689
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
G. Blumenschein (2008)
10.1200/JCO.2010.28.15_SUPPL.3003
A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.
J. Baselga (2010)
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.
M. Scartozzi (2010)
10.1200/JCO.2010.28.15_SUPPL.2589
Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.
U. Swami (2010)
10.1056/NEJMoa1006448
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L. Kwak (2010)
10.1517/13543781003767434
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
C. Gridelli (2010)
10.1038/sj.bjc.6605650
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
G. Rustin (2010)
10.1158/0008-5472.CAN-05-1215
In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor.
Z. Dikmen (2005)
10.1200/JCO.2009.27.15_SUPPL.3558
Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179.
A. Oza (2009)
10.1158/1078-0432.CCR-10-1706
Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features
C. Rudin (2011)
10.1200/JCO.2007.12.2614
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
R. Ramlau (2008)
10.1073/pnas.0707140104
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming
D. Atanackovic (2008)
10.1038/nrc2964
Shared and separate functions of polo-like kinases and aurora kinases in cancer
S. Lens (2010)
10.1200/JCO.2009.23.9749
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
N. Altorki (2010)
10.1038/311029A0
Molecular cloning of a new transforming gene from a chemically transformed human cell line
C. Cooper (1984)
A randomized phase II study of paclitaxel and carboplatin Ϯ bevacizumab Ϯ dulanermin in non-small cell lung cancer
F H Blackhall (2010)
Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study
G Scagliotti (2010)
Phase II study of the efficacy and safety of intravenous (IV) AVE005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum-and erlotinib-resistant adenocarcinoma of the lung
E Massarelli (2007)
10.1200/JCO.2009.26.7609
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
10.1002/cncr.21407
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein: A phase II clinical trial
O. Altundag (2005)
10.1158/0008-5472.CAN-07-5031
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
C. L. Hann (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar